SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Andreasson Bjorn) "

Sökning: WFRF:(Andreasson Bjorn)

  • Resultat 1-10 av 23
  • [1]23Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Andersen, Christen Lykkegaard, et al. (författare)
  • Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat
  • 2014
  • Ingår i: Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. - 0145-2126 .- 1873-5835. ; 38:7, s. 816-821
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P&lt;0.0001) and 1.7 times higher than in ET (P = 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms. (C) 2014 Elsevier Ltd. All rights reserved.</p>
  •  
2.
  • Andersen, Christen Lykkegaard, et al. (författare)
  • Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat
  • 2014
  • Ingår i: Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. - Elsevier. - 0145-2126 .- 1873-5835. ; 38:7, s. 816-821
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P&lt;0.0001) and 1.7 times higher than in ET (P = 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.</p>
  •  
3.
  • Merup, Mats, et al. (författare)
  • Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens
  • 2006
  • Ingår i: British Journal of Haematology. - Federation of European Neuroscience Societies and Blackwell Publishing Ltd. - 0007-1048. ; 135:3, s. 367-373
  • Tidskriftsartikel (refereegranskat)abstract
    • Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted; 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations.
  •  
4.
  • Abelsson, Johanna, et al. (författare)
  • Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms
  • 2013
  • Ingår i: Leukemia and Lymphoma. - 1042-8194 .- 1029-2403. ; 54:10, s. 2226-2230
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>The quality of life (QoL) at the time of diagnosis of myeloproliferative neoplasm (MPN) has, to date, not been studied. One hundred and seventy-nine patients with MPN: 80 with essential thrombocythemia (ET), 73 with polycythemia vera (PV), 22 with primary myelofibrosis (PMF) and four with MPN undifferentiated, were included in this study. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQC30) and the MPN-Symptom Assessment Form (MPN-SAF) were used to evaluate QoL. Fatigue was the most reported symptom in these patients. Patients with PV reported significantly higher mean scores for inactivity, dizziness, cough, itching, depression and lower total QoL compared to patients with ET. Patients with PV had significantly more headache and itching compared to patients with PMF. When the newly diagnosed patients with MPN were compared with a cohort of patients with MPN with mean disease duration of 7.8 years, the differences were most striking for patients with PMF, with significantly more fatigue, abdominal discomfort, concentration problems, insomnia, fever, weight loss and lower overall QoL developed over time.</p>
  •  
5.
  • Ahlstrand, Erik, et al. (författare)
  • Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up
  • 2020
  • Ingår i: European Journal of Haematology. - WILEY. - 0902-4441 .- 1600-0609. ; 104:3, s. 271-278
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Objective To explore the relative importance of risk factors, treatments, and blood counts for the occurrence of vascular complications and their impact on life expectancy in essential thrombocythemia (ET) and polycythemia vera (PV). Methods Nested case-control study within the Swedish MPN registry. From a cohort of 922 ET patients and 763 PV patients, 71 ET and 81 PV cases with vascular complications were compared with matched controls. Results Incidence of vascular complications was 2.0 and 3.4 events per 100 patient-years in ET and PV, respectively. At diagnosis, no significant risk factor differences were observed between cases and controls in neither of the diseases. At the time of vascular event, ET complication cases did not differ significantly from controls but in PV, cases had significantly higher WBCs and were to a lesser extent treated with anti-thrombotic and cytoreductive therapy. Life expectancy was significantly decreased in both ET and PV cases compared with controls. Conclusions The risk of vascular complications is high in both ET and PV, and these complications have a considerable impact on life expectancy. The protective effect of anti-thrombotic and cytoreductive therapy for vascular complications in PV underscores the importance of avoiding undertreatment.</p>
  •  
6.
  •  
7.
  • Andersen, Christen L., et al. (författare)
  • A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
  • 2013
  • Ingår i: British Journal of Haematology. - 0007-1048 .- 1365-2141. ; 162:4, s. 498-508
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Inhibition of histone deacetylases may be an important target in patients with myeloproliferative neoplasms. This investigator-initiated, non-randomized, open-label phase II multi-centre study included 63 patients (19 essential thrombocythaemia, 44 polycythaemia vera) from 15 centres. The primary objective was to evaluate if vorinostat was followed by a decline in clonal myeloproliferation as defined by European Leukaemia Net. Thirty patients (48%) completed the intervention period (24 weeks of therapy). An intention-to-treat response rate of 35% was identified. Pruritus was resolved [19% to 0% (P=0.06)] and the prevalence of splenomegaly was lowered from 50% to 27% (P=0.03). Sixty-five per cent of the patients experienced a decrease in JAK2 V617F allele burden (P=0.006). Thirty-three patients (52% of patients) discontinued study drug before end of intervention due to adverse events (28 patients) or lack of response (5 patients). In conclusion, vorinostat showed effectiveness by normalizing elevated leucocyte and platelet counts, resolving pruritus and significantly reducing splenomegaly. However, vorinostat was associated with significant side effects resulting in a high discontinuation rate. A lower dose of vorinostat in combination with conventional and/or novel targeted therapies may be warranted in future studies.</p>
  •  
8.
  • Andersen, Christen L., et al. (författare)
  • A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
  • 2013
  • Ingår i: British Journal of Haematology. - American Society of Hematology. - 0007-1048 .- 1365-2141. ; 162:4, s. 498-508
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Inhibition of histone deacetylases may be an important target in patients with myeloproliferative neoplasms. This investigator-initiated, non-randomized, open-label phase II multi-centre study included 63 patients (19 essential thrombocythaemia, 44 polycythaemia vera) from 15 centres. The primary objective was to evaluate if vorinostat was followed by a decline in clonal myeloproliferation as defined by European Leukaemia Net. Thirty patients (48%) completed the intervention period (24 weeks of therapy). An intention-to-treat response rate of 35% was identified. Pruritus was resolved [19% to 0% (P=0.06)] and the prevalence of splenomegaly was lowered from 50% to 27% (P=0.03). Sixty-five per cent of the patients experienced a decrease in JAK2 V617F allele burden (P=0.006). Thirty-three patients (52% of patients) discontinued study drug before end of intervention due to adverse events (28 patients) or lack of response (5 patients). In conclusion, vorinostat showed effectiveness by normalizing elevated leucocyte and platelet counts, resolving pruritus and significantly reducing splenomegaly. However, vorinostat was associated with significant side effects resulting in a high discontinuation rate. A lower dose of vorinostat in combination with conventional and/or novel targeted therapies may be warranted in future studies.</p>
  •  
9.
  • Birgegard, Gunnar, et al. (författare)
  • Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group
  • 2019
  • Ingår i: European Journal of Haematology. - WILEY. - 0902-4441 .- 1600-0609. ; 102:3, s. 235-240
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Objectives The study investigates the hypothesis that inflammation in myelofibrosis (MF) like in myeloma and lymphoma, may disturb iron distribution and contribute to anaemia. Methods A cross-sectional study of 80 MF and 23 ET patients was performed. Results About 35% of anaemic MF patients had functional iron deficiency (FID) with transferrin saturation amp;lt;20 and normal or elevated S-ferritin (amp;lt;500 mu g/L). In ET, FID was rare. In MF patients with FID, 70.6% were anaemic, vs 29.4% in patients without FID (P = 0.03). Hepcidin was significantly higher in MF patients with anaemia, including transfusion-dependent patients, 50.6 vs 24.4 mu g/L (P = 0.01). There was a significant negative correlation between Hb and inflammatory markers in all MF patients: IL-2, IL-6 and TNF-alpha, (P amp;lt; 0.01-0.03), LD (P = 0.004) and hepcidin (P = 0.03). These correlations were also seen in the subgroup of anaemic MF patients (Table ). Tsat correlated negatively with CRP (P amp;lt; 0.001). Symptom burden was heavier in MF patients with FID, and MPN-SAF quality of life scores correlated with IL-6 and CRP. Conclusions The inflammatory state of MF disturbs iron turnover, FID is common and contributes to anaemia development and impairment of QoL. Anaemic MF patients should be screened for FID.</p>
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 23
  • [1]23Nästa
Åtkomst
fritt online (1)
Typ av publikation
tidskriftsartikel (23)
Typ av innehåll
refereegranskat (21)
övrigt vetenskapligt (4)
Författare/redaktör
Andreasson, Bjorn (21)
Samuelsson, Jan (17)
Zweegman, Sonja (12)
Passamonti, Francesc ... (10)
Vannucchi, Alessandr ... (10)
Harrison, Claire N., (10)
visa fler...
Cervantes, Francisco (9)
Kiladjian, Jean-Jacq ... (9)
Rambaldi, Alessandro (9)
Dueck, Amylou C. (9)
Birgegård, Gunnar, (8)
Barbui, Tiziano (8)
Barosi, Giovanni (8)
Reiter, Andreas (8)
Besses, Carlos (8)
Xiao, Zhijian (8)
Ejerblad, Elisabeth, (7)
Griesshammer, Martin (7)
Cahn, Jean-Yves (7)
Slot, Stefanie (7)
Sackmann, Federico (7)
Stegelmann, Frank (7)
Lehmann, Thomas (7)
Bonatz, Karin (7)
Boyer, Francoise (7)
Etienne, Gabriel (7)
Ranta, Dana (7)
Roy, Lydia (7)
Zhang, Yue (6)
Kerguelen Fuentes, A ... (6)
Pahl, Heike L. (6)
Ianotto, Jean-Christ ... (6)
Ahlstrand, Erik (5)
Linder, Olle (5)
Gale, Robert Peter (5)
Schouten, Harry C (5)
Commandeur, Suzan (5)
Doehner, Konstanze (5)
Xu, Zefeng (5)
Johansson, Peter (4)
Harrison, Claire (4)
Fernandes, Savio (4)
Bareford, David (4)
Knapper, Steven (4)
Vestergaard, Hanne (4)
Larsen, Herdis (4)
Mourits-Andersen, To ... (4)
Tefferi, Ayalew (4)
Radia, Deepti H. (4)
Ferarri, Maria L. (4)
visa färre...
Lärosäte
Uppsala universitet (15)
Lunds universitet (3)
Göteborgs universitet (2)
Örebro universitet (2)
Linköpings universitet (2)
Karolinska Institutet (2)
Språk
Engelska (23)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (22)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy